Tyra Biosciences, Inc. - Common Stock, $0.0001 par value per share (the "Shares") (TYRA)

Q: What does CUSIP 90240B106 represent in this 13F holders report?

CUSIP 90240B106 is the security identifier for TYRA - Tyra Biosciences, Inc. - Common Stock, $0.0001 par value per share (the "Shares") used to aggregate holder disclosures.

Q: How many institutions held TYRA - Tyra Biosciences, Inc. - Common Stock, $0.0001 par value per share (the "Shares") in Q3 2025?

115 institutional investors reported TYRA - Tyra Biosciences, Inc. - Common Stock, $0.0001 par value per share (the "Shares") for Q3 2025. Use the holders table for investor-level position and value details.

CUSIP: 90240B106

Q3 2025 13F Holders as of 30 Sep 2025

Type / Class: Equity / Common Stock, $0.0001 par value per share (the "Shares")
Shares outstanding: 54,254,818
Total 13F shares: 55,638,635
Share change: -1,109,953
Total reported value: $778,399,313
Price per share: $13.99
Number of holders: 115
Value change: -$9,877,671
Number of buys: 47
Number of sells: 52

Quarterly Holders Quick Answers

What is CUSIP 90240B106?
CUSIP 90240B106 identifies TYRA - Tyra Biosciences, Inc. - Common Stock, $0.0001 par value per share (the "Shares") in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q4 2025
Previous quarter: Q2 2025

Recent filing periods for CUSIP 90240B106:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of TYRA - Tyra Biosciences, Inc. - Common Stock, $0.0001 par value per share (the "Shares") (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Boxer Capital Management, LLC	3/4/5	Other*	— mixed-class rows	7,153,639 mixed-class rows	$125,264,455	—	18 Oct 2024	3/4/5
Nina S. Kjellson	3/4/5	Director	— mixed-class rows	7,975,964 mixed-class rows	$122,459,032	—	05 Feb 2025	3/4/5
RA CAPITAL MANAGEMENT, L.P.	3/4/5 13F	Director, 10%+ Owner · Company	22% from 13F	11,281,491 mixed-class rows	$116,935,617	+$15,320,006	12 Jun 2025	3/4/5 13F
Boxer Capital, LLC	3/4/5	Other*	— mixed-class rows	7,239,578 mixed-class rows	$94,186,205	—	06 Feb 2024	3/4/5
Commodore Capital LP	13D/G 13F	Company	6.3%	3,375,000	$47,216,250	+$8,743,750	30 Sep 2025	13D/G 13F
Alta Partners Management Company, L.P.	13F	Company	7.5%	4,080,296	$39,048,433	—	30 Jun 2025	13F
Nextech Invest, Ltd.	13F	Company	7.5%	4,055,861	$38,814,590	—	30 Jun 2025	13F
BVF INC/IL	13F	Company	7.3%	3,944,194	$37,745,937	—	30 Jun 2025	13F
Canaan Partners XI LLC	13F	Company	6.7%	3,608,109	$34,529,603	—	30 Jun 2025	13F
Vestal Point Capital, LP	13D/G 13F	Company	4.5%	2,425,000	$33,925,750	-$6,363,058	30 Sep 2025	13D/G 13F
TCG Crossover GP I, LLC	13D/G	—	5.7%	2,898,103	$29,792,499	$0	27 Feb 2025	13D/G
JANUS HENDERSON GROUP PLC	13D/G 13F	Company	5.4%	2,856,290	$29,305,535	+$1,672,924	30 Jun 2025	13D/G 13F
TCG Crossover Management, LLC	13F	Company	5.3%	2,898,103	$27,734,846	—	30 Jun 2025	13F
Alta Partners NextGen Fund II Management, LLC	3/4/5	10%+ Owner	— class O/S missing	4,080,296	$26,844,267	—	17 Sep 2021	3/4/5
Kynam Capital Management, LP	13F	Company	4.3%	2,329,998	$22,298,081	—	30 Jun 2025	13F
BlackRock, Inc.	13F	Company	3.5%	1,893,328	$18,119,150	—	30 Jun 2025	13F
VANGUARD GROUP INC	13F	Company	2.6%	1,401,693	$13,414,202	—	30 Jun 2025	13F
FARALLON CAPITAL MANAGEMENT LLC	13F	Company	2.1%	1,143,818	$10,946,338	—	30 Jun 2025	13F
5AM Venture Management, LLC	13F	Company	1.7%	939,298	$8,989,082	—	30 Jun 2025	13F
Sio Capital Management, LLC	13F	Company	1.5%	810,274	$7,754,322	—	30 Jun 2025	13F
ORBIMED ADVISORS LLC	13F	Company	1.5%	804,603	$7,700,051	—	30 Jun 2025	13F
Cormorant Asset Management, LP	3/4/5	Former 10% Owner	— class O/S missing	1,069,932	$7,039,083	—	17 Sep 2021	3/4/5
BALYASNY ASSET MANAGEMENT L.P.	13F	Company	1.1%	583,386	$5,583,004	—	30 Jun 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1%	567,126	$5,428,267	—	30 Jun 2025	13F
MARSHALL WACE, LLP	13F	Company	0.79%	428,108	$4,096,994	—	30 Jun 2025	13F
STATE STREET CORP	13F	Company	0.77%	418,984	$4,009,677	—	30 Jun 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.75%	407,464	$3,899,430	—	30 Jun 2025	13F
JACOBS LEVY EQUITY MANAGEMENT, INC	13F	Company	0.73%	395,299	$3,783,011	—	30 Jun 2025	13F
MORGAN STANLEY	13F	Company	0.7%	378,402	$3,621,308	—	30 Jun 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.69%	372,967	$3,569,293	—	30 Jun 2025	13F
Walleye Capital LLC	13F	Company	0.68%	370,408	$3,544,805	—	30 Jun 2025	13F
Canaan XI L.P.	3/4/5	10%+ Owner	— class O/S missing	473,396	$3,114,472	—	17 Sep 2021	3/4/5
Point72 Asset Management, L.P.	13F	Company	0.41%	224,700	$2,150,379	—	30 Jun 2025	13F
CITADEL ADVISORS LLC	13F	Company	0.4%	216,136	$2,068,422	—	30 Jun 2025	13F
NORTHERN TRUST CORP	13F	Company	0.38%	205,308	$1,964,797	—	30 Jun 2025	13F
Caligan Partners LP	13F	Company	0.35%	189,950	$1,817,822	—	30 Jun 2025	13F
Robert L. Hudkins	3/4/5	Chief Technology Officer	— class O/S missing	273,576	$1,799,857	—	15 Sep 2022	3/4/5
Ronald Swanson V	3/4/5	Chief Scientific Officer	— mixed-class rows	378,254 mixed-class rows	$1,797,738	—	06 Sep 2022	3/4/5
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.33%	178,104	$1,704,455	—	30 Jun 2025	13F
Esther van den Boom	3/4/5	Chief Financial Officer	— class O/S missing	240,542	$1,582,525	—	15 Sep 2022	3/4/5
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.25%	135,100	$1,292,907	—	30 Jun 2025	13F
AXA S.A.	13F	Company	0.24%	128,400	$1,228,788	—	30 Jun 2025	13F
Cubist Systematic Strategies, LLC	13F	Company	0.22%	122,036	$1,167,885	—	30 Jun 2025	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.2%	105,825	$1,012,745	—	30 Jun 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.19%	105,595	$1,010,544	—	30 Jun 2025	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	0.19%	103,078	$986,457	—	30 Jun 2025	13F
JPMORGAN CHASE & CO	13F	Company	0.19%	102,917	$984,915	—	30 Jun 2025	13F
Woodline Partners LP	13F	Company	0.18%	100,108	$958,034	—	30 Jun 2025	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0.18%	97,736	$935,334	—	30 Jun 2025	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.16%	87,000	$832,590	—	30 Jun 2025	13F

Institutional Holders of Tyra Biosciences, Inc. - Common Stock, $0.0001 par value per share (the "Shares") (TYRA) as of Q3 2025

As of 30 Sep 2025, Tyra Biosciences, Inc. - Common Stock, $0.0001 par value per share (the "Shares") (TYRA) was held by 115 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 55,638,635 shares. The largest 10 holders included RA CAPITAL MANAGEMENT, L.P., Alta Partners Management Company, L.P., Nextech Invest, Ltd., BVF INC/IL, Canaan Partners XI LLC, Commodore Capital LP, TCG Crossover Management, LLC, JANUS HENDERSON GROUP PLC, Vestal Point Capital, LP, and Kynam Capital Management, LP. This page lists 115 institutional shareholders reporting positions in this security for the Q3 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q3 2025 vs Q2 2025 Across Filers

Q2 2025 holders

120

Q3 2025 holders

115

Holder diff

-5

Investor	Q2 2025 Shares	Q3 2025 Shares	Share Diff	Share Chg %	Q2 2025 Value $	Q3 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.